AT1 antagonist modulates activin-like kinase 5 and TGF-β receptor II in the developing kidney

Hyung-Eun Yim, Mee Kyung Kim, In Sun Bae, Ji Hae Kim, Byung Min Choi, Kee Hwan Yoo, Young Sook Hong, Joo Won Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Previous studies by our group have demonstrated that angiotensin-converting enzyme (ACE) inhibition in the developing kidney modulates transforming growth factor-β receptors. Blocking of angiotensin II (ANG II) mainly through angiotensin II type 1 receptor (AT1) has been implicated in mediating this ACE inhibition. The present study was designed to investigate the effects of an AT1 antagonist, losartan, on transforming growth factor-β1 (TGF-β1), TGF-β receptor I [TβRI, activin-like kinase (ALK)-1, ALK-5], TGF-β receptor II (TβRII), and α-smooth muscle actin (α-SMA) expression in the developing kidney. Newborn rat pups were treated with losartan (30 mg/kg per day) or normal saline for 7 days. Kidneys were removed for immunohistochemistry, reverse transcription polymerase chain reaction (PCR), and Western blotting of TGF-β1, ALK-1, ALK-5, TβRII, and α-SMA. Renal ALK-5 and TβRII protein expressions in the losartan-treated group were found to be significantly increased (P<0.05), whereas TGF-β1, ALK-1, and α-SMA protein expressions were not changed by losartan treatment. The losartan-treated group also showed significantly increased mean tubular diameter and interstitial area of the kidney (P<0.05). These results suggest that AT1 inhibition in the developing kidney impairs renal growth and development and modulates the expression of ALK-5 and TβRII.

Original languageEnglish
Pages (from-to)1377-1388
Number of pages12
JournalPediatric Nephrology
Volume21
Issue number10
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

Losartan
Kidney
Transforming Growth Factors
Activins
Phosphotransferases
Peptidyl-Dipeptidase A
Angiotensin Type 1 Receptor
Growth Factor Receptors
TGF-beta type I receptor
Growth and Development
Angiotensin II
Reverse Transcription
Smooth Muscle
Actins
Proteins
Western Blotting
Immunohistochemistry
Polymerase Chain Reaction

Keywords

  • Angiotensin II type 1 receptor
  • TGF-β receptors
  • Transforming growth factor-β1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

AT1 antagonist modulates activin-like kinase 5 and TGF-β receptor II in the developing kidney. / Yim, Hyung-Eun; Kim, Mee Kyung; Bae, In Sun; Kim, Ji Hae; Choi, Byung Min; Yoo, Kee Hwan; Hong, Young Sook; Lee, Joo Won.

In: Pediatric Nephrology, Vol. 21, No. 10, 01.10.2006, p. 1377-1388.

Research output: Contribution to journalArticle

Yim, Hyung-Eun ; Kim, Mee Kyung ; Bae, In Sun ; Kim, Ji Hae ; Choi, Byung Min ; Yoo, Kee Hwan ; Hong, Young Sook ; Lee, Joo Won. / AT1 antagonist modulates activin-like kinase 5 and TGF-β receptor II in the developing kidney. In: Pediatric Nephrology. 2006 ; Vol. 21, No. 10. pp. 1377-1388.
@article{535027a66b1844979f7aa2363bacb13b,
title = "AT1 antagonist modulates activin-like kinase 5 and TGF-β receptor II in the developing kidney",
abstract = "Previous studies by our group have demonstrated that angiotensin-converting enzyme (ACE) inhibition in the developing kidney modulates transforming growth factor-β receptors. Blocking of angiotensin II (ANG II) mainly through angiotensin II type 1 receptor (AT1) has been implicated in mediating this ACE inhibition. The present study was designed to investigate the effects of an AT1 antagonist, losartan, on transforming growth factor-β1 (TGF-β1), TGF-β receptor I [TβRI, activin-like kinase (ALK)-1, ALK-5], TGF-β receptor II (TβRII), and α-smooth muscle actin (α-SMA) expression in the developing kidney. Newborn rat pups were treated with losartan (30 mg/kg per day) or normal saline for 7 days. Kidneys were removed for immunohistochemistry, reverse transcription polymerase chain reaction (PCR), and Western blotting of TGF-β1, ALK-1, ALK-5, TβRII, and α-SMA. Renal ALK-5 and TβRII protein expressions in the losartan-treated group were found to be significantly increased (P<0.05), whereas TGF-β1, ALK-1, and α-SMA protein expressions were not changed by losartan treatment. The losartan-treated group also showed significantly increased mean tubular diameter and interstitial area of the kidney (P<0.05). These results suggest that AT1 inhibition in the developing kidney impairs renal growth and development and modulates the expression of ALK-5 and TβRII.",
keywords = "Angiotensin II type 1 receptor, TGF-β receptors, Transforming growth factor-β1",
author = "Hyung-Eun Yim and Kim, {Mee Kyung} and Bae, {In Sun} and Kim, {Ji Hae} and Choi, {Byung Min} and Yoo, {Kee Hwan} and Hong, {Young Sook} and Lee, {Joo Won}",
year = "2006",
month = "10",
day = "1",
doi = "10.1007/s00467-006-0197-0",
language = "English",
volume = "21",
pages = "1377--1388",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - AT1 antagonist modulates activin-like kinase 5 and TGF-β receptor II in the developing kidney

AU - Yim, Hyung-Eun

AU - Kim, Mee Kyung

AU - Bae, In Sun

AU - Kim, Ji Hae

AU - Choi, Byung Min

AU - Yoo, Kee Hwan

AU - Hong, Young Sook

AU - Lee, Joo Won

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Previous studies by our group have demonstrated that angiotensin-converting enzyme (ACE) inhibition in the developing kidney modulates transforming growth factor-β receptors. Blocking of angiotensin II (ANG II) mainly through angiotensin II type 1 receptor (AT1) has been implicated in mediating this ACE inhibition. The present study was designed to investigate the effects of an AT1 antagonist, losartan, on transforming growth factor-β1 (TGF-β1), TGF-β receptor I [TβRI, activin-like kinase (ALK)-1, ALK-5], TGF-β receptor II (TβRII), and α-smooth muscle actin (α-SMA) expression in the developing kidney. Newborn rat pups were treated with losartan (30 mg/kg per day) or normal saline for 7 days. Kidneys were removed for immunohistochemistry, reverse transcription polymerase chain reaction (PCR), and Western blotting of TGF-β1, ALK-1, ALK-5, TβRII, and α-SMA. Renal ALK-5 and TβRII protein expressions in the losartan-treated group were found to be significantly increased (P<0.05), whereas TGF-β1, ALK-1, and α-SMA protein expressions were not changed by losartan treatment. The losartan-treated group also showed significantly increased mean tubular diameter and interstitial area of the kidney (P<0.05). These results suggest that AT1 inhibition in the developing kidney impairs renal growth and development and modulates the expression of ALK-5 and TβRII.

AB - Previous studies by our group have demonstrated that angiotensin-converting enzyme (ACE) inhibition in the developing kidney modulates transforming growth factor-β receptors. Blocking of angiotensin II (ANG II) mainly through angiotensin II type 1 receptor (AT1) has been implicated in mediating this ACE inhibition. The present study was designed to investigate the effects of an AT1 antagonist, losartan, on transforming growth factor-β1 (TGF-β1), TGF-β receptor I [TβRI, activin-like kinase (ALK)-1, ALK-5], TGF-β receptor II (TβRII), and α-smooth muscle actin (α-SMA) expression in the developing kidney. Newborn rat pups were treated with losartan (30 mg/kg per day) or normal saline for 7 days. Kidneys were removed for immunohistochemistry, reverse transcription polymerase chain reaction (PCR), and Western blotting of TGF-β1, ALK-1, ALK-5, TβRII, and α-SMA. Renal ALK-5 and TβRII protein expressions in the losartan-treated group were found to be significantly increased (P<0.05), whereas TGF-β1, ALK-1, and α-SMA protein expressions were not changed by losartan treatment. The losartan-treated group also showed significantly increased mean tubular diameter and interstitial area of the kidney (P<0.05). These results suggest that AT1 inhibition in the developing kidney impairs renal growth and development and modulates the expression of ALK-5 and TβRII.

KW - Angiotensin II type 1 receptor

KW - TGF-β receptors

KW - Transforming growth factor-β1

UR - http://www.scopus.com/inward/record.url?scp=33747812916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747812916&partnerID=8YFLogxK

U2 - 10.1007/s00467-006-0197-0

DO - 10.1007/s00467-006-0197-0

M3 - Article

C2 - 16897002

AN - SCOPUS:33747812916

VL - 21

SP - 1377

EP - 1388

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 10

ER -